- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05775874
A Study to Evaluate the Safety and Efficacy of AZD4547 Combination With Tislelizumab in Patients With mUC
A Sigle-arm,Open Label,Multicenter Study of AZD4547 Combination With Tislelizumab for Patients With Metastatic or Locally Advanced Urothelial Carcinoma (mUC) Harboring Fibroblast Growth Factor Receptor Alterations
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Yuan Lu, Director
- Phone Number: 021-68910052
- Email: clinical@abbisko.cn
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200032
- Recruiting
- Fudan University Shanghai Cancer Center
-
Contact:
- Dingwei Ye, Professor
- Phone Number: 02164175590
- Email: dwyeli@163.com
-
Principal Investigator:
- Dingwei Ye, professor
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Volunteer to participate in this clinical trial, understand the study procedures, and be able to sign a written informed consent.
- Age of 25 years old at the time of signing the informed consent (or the age range specifically required by the regulatory agency or ethics), without gender limitation;
- By histologically confirmed, surgical unresectable local advanced or metastatic urothelial cancer patients, can be accompanied by other histological type differentiation (including adenoid, squamous or other types)
- The ECOG PS (performance status) score is 0-1 point;
- The estimated survival period of 3 months;
- Good organ function level meets the following laboratory examination requirements, and the examination results should be obtained within 14 days before the first administration of the study treatment
- Fertility female or male subjects must agree to use a medically approved contraceptive measure during the study treatment and within 6 months after the end of the study treatment period; fertile female subjects must have a negative blood β -hCG test within 7 days before the first dose and must be non-lactating;
Exclusion Criteria:
- Known allergic to AZD4547 tablets or components; allergic to monoclonal antibody drugs and fusion protein drugs.
- Patients with imaging progression after previously receiving selective FGFR inhibitors or receiving immune checkpoint inhibitors
- Subjects with a history of an active autoimmune disease or a possible recurrence of an autoimmune disease, as judged by the investigator, should be excluded. Patients are admitted for the following diseases: hypothyroidism that can be controlled by hormone replacement therapy only, skin diseases without systemic treatment
- A history of idiopathic pulmonary fibrosis (including pneumonia), drug-related pneumonia, organic pneumonia
- Subjects requiring systemic treatment with corticosteroids (prednisone or similar drug> 10 mg / day) or other immunosuppressive agents within 14 days prior to enrollment.a)
- Other malignant tumors requiring treatment were present within 6. 3 years
7 The electrolyte disorders that cannot be corrected and affect serum potassium, blood calcium or blood phosphorus levels.
8. Unstable or symptomatic CNS transfer
9. The researchers judge that the subject has factors that significantly affect the absorption of oral drugs.
10 Current active infection or fever of unknown origin> 38.5℃
11. Previous allograft or stem cell transplantation or organ transplantation.
12. Use of any live or attenuated vaccine against infectious diseases (e. g., influenza, chickenpox, etc.)
13. End time of other anti-tumor treatment from first study drug:
14. Patients with reversible adverse events caused by previous antitumor therapy, not returning to grade CTCAE
15 Patients are using, or are using, the following drugs or foods within 7 days before the first administration of the study treatment: CYP3A4 and CYP2D6 strong inhibitors or inducers.
16. Presence of uncontrolled cardiovascular disease or medical history, including: a) Congestive heart failure
17. Any abnormal corneal or retinal changes that may increase the risk of ocular toxicity during screening, including:
18. Human immunodeficiency virus (HIV) infection (HIV antibody serotest positive) or previously acquired / hereditary immunodeficiency disease
19 Patients with refractory / uncontrolled ascites or pleural effusion. Patients were allowed to use an indwelling catheter.
20 Severe unhealed skin / mucosal ulcers, chronic ulcers of the lower extremities, known gastric ulcers, or incisions are present.
21. Any other medical treatment (e. g., respiratory, metabolic, infectious, immune, congenital, endocrine, or central nervous system diseases), mental or social factors that may sign informed consent, cooperation, participate in clinical studies or affect the interpretation of the research results.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: An open evaluation of AZD4547 combined with Tislelizumab in UC patients
AZD4547 : Initiation dose 80mg BID,po;Until disease progression, death, loss to follow-up, voluntary withdrawal of informed consent, development of intolerable toxicity, investigator decision to discontinue treatment, or completion of the entire study. Tislelizumab:200mg Q3W, Until disease progression, death, loss to follow-up, voluntary withdrawal of informed consent, development of intolerable toxicity, investigator decision to discontinue treatment, or completion of the entire study. |
Initiation dose: 80mg BID,po.
Other Names:
Tislelizumab:200mg Q3W
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety index
Time Frame: At the end of Cycle 1 (each cycle is 28 days)
|
Part A:Dose limiting toxicity (DLT) incidence
|
At the end of Cycle 1 (each cycle is 28 days)
|
Effectiveness indicators
Time Frame: at least 8 weeks
|
Part B: Objective remission rate
|
at least 8 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Dingwei Ye, Professor, Fudan University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ABSK091-203
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Urothelial Carcinoma
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Active, not recruitingMetastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Metastatic Urothelial Carcinoma | Locally Advanced Bladder Urothelial Carcinoma | Locally Advanced Renal Pelvis Urothelial... and other conditionsUnited States
-
Roswell Park Cancer InstituteIovance Biotherapeutics, Inc.WithdrawnMetastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Unresectable Renal Pelvis Urothelial Carcinoma | Unresectable Ureter Urothelial CarcinomaUnited States
-
University of UtahNational Cancer Institute (NCI)RecruitingMetastatic Urothelial Carcinoma | Locally Advanced Urothelial Carcinoma | Unresectable Urothelial Carcinoma | Infiltrating Urothelial Carcinoma, Sarcomatoid VariantUnited States
-
National Cancer Institute (NCI)Active, not recruitingMetastatic Urothelial Carcinoma | Stage III Bladder Urothelial Carcinoma AJCC v6 and v7 | Stage IV Bladder Urothelial Carcinoma AJCC v7 | Locally Advanced Urothelial Carcinoma | Recurrent Urothelial Carcinoma | Unresectable Urothelial Carcinoma | Advanced Urothelial CarcinomaUnited States
-
Emory UniversityNational Cancer Institute (NCI); ExelixisRecruitingMetastatic Urothelial Carcinoma | Locally Advanced Urothelial Carcinoma | Unresectable Urothelial Carcinoma | Infiltrating Bladder Urothelial Carcinoma With Squamous DifferentiationUnited States
-
National Cancer Institute (NCI)Active, not recruitingMetastatic Bladder Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Stage IV Bladder Urothelial Carcinoma AJCC v7 | Metastatic Renal Pelvis and Ureter Urothelial CarcinomaUnited States
-
Mamta ParikhNational Cancer Institute (NCI); Karyopharm Therapeutics IncRecruitingMetastatic Urothelial Carcinoma | Locally Advanced Urothelial Carcinoma | Advanced Urothelial Carcinoma | Refractory Urothelial CarcinomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingMetastatic Urothelial Carcinoma | Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant | Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant | Infiltrating Bladder Urothelial Carcinoma With Glandular Differentiation | Infiltrating Bladder Urothelial Carcinoma With Squamous... and other conditionsUnited States
-
Mayo ClinicNational Cancer Institute (NCI)WithdrawnInfiltrating Bladder Urothelial Carcinoma | Stage II Bladder Urothelial Carcinoma | Stage IV Bladder Urothelial Carcinoma | Stage III Bladder Urothelial CarcinomaUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedStage II Bladder Urothelial Carcinoma | Stage III Bladder Urothelial Carcinoma | Stage 0is Bladder Urothelial Carcinoma | Stage I Bladder Urothelial CarcinomaUnited States
Clinical Trials on AZD4547
-
National Cancer Institute (NCI)CompletedHematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Plasma Cell MyelomaUnited States
-
AstraZenecaCompletedCancer | Advanced Solid MalignanciesJapan
-
AstraZenecaTerminatedCancer | Advanced Solid MalignanciesUnited States, Italy, United Kingdom, France, Germany, Spain, Netherlands
-
Abbisko Therapeutics Co, LtdRecruitingUrothelial CarcinomaChina
-
Abbisko Therapeutics Co, LtdCompleted
-
Southwest Oncology GroupNational Cancer Institute (NCI)CompletedRecurrent Squamous Cell Lung Carcinoma | Stage IV Squamous Cell Lung Carcinoma AJCC v7 | FGFR1 Gene Amplification | FGFR2 Gene Amplification | FGFR2 Gene Mutation | FGFR3 Gene Mutation | FGFR1 Gene Mutation | FGFR3 Gene AmplificationUnited States, Canada
-
AstraZenecaTerminatedGastric Cancer | Gastro-oesophageal Junction CancerBulgaria, Czech Republic, Italy, Korea, Republic of, Spain, United Kingdom, Hungary, Romania, Ukraine, Belgium, Canada, Germany, Taiwan, India, Japan, France
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)CompletedRecurrent Non-small Cell Lung Cancer | Squamous Cell Lung CancerUnited States
-
AstraZenecaActive, not recruitingMuscle Invasive Bladder CancerSpain, United States, Canada, France, United Kingdom
-
Assistance Publique - Hôpitaux de ParisCompletedRecurrent IDHwt Gliomas With FGFR3-TACC3 Fusion | Recurrent IDHwt Gliomas With FGFR1-TACC1 FusionFrance